Welcome to our dedicated page for Meiragtx Holdings Plc SEC filings (Ticker: MGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MeiraGTx Holdings plc (Nasdaq: MGTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage genetic medicines company with programs in ophthalmology, Parkinson’s disease and radiation-induced xerostomia, MeiraGTx uses SEC reports to communicate material events, financial results and key collaboration agreements to investors.
Among the filings available are current reports on Form 8-K, which MeiraGTx has used to announce quarterly financial and operational results, strategic collaborations and regulatory milestones. For example, the company has filed 8-Ks describing its strategic collaboration and license agreement with Eli Lilly and Company in ophthalmology, its broad collaboration with Hologen Limited to form Hologen Neuro AI Ltd, and the receipt of foreign direct investment clearances related to that collaboration. Other 8-Ks reference the release of financial results for specific quarters.
In addition to current reports, investors can use this page to locate MeiraGTx’s periodic filings, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, when available. These documents typically contain detailed discussions of the company’s clinical pipeline, including programs like AAV-AIPL1, AAV2-hAQP1 and AAV-GAD, as well as risk factors, management’s discussion and analysis, and information on its manufacturing infrastructure and collaborations.
Stock Titan enhances access to these filings by providing real-time updates from the SEC’s EDGAR system and AI-powered summaries that explain the key points in plain language. Users can quickly see which filings relate to clinical data, regulatory designations, strategic partnerships or financing. The filings page also surfaces information on items such as material definitive agreements, like the collaboration and license agreement with Eli Lilly, and other disclosures that may affect MeiraGTx’s development plans and capital position.
For those tracking MeiraGTx’s progress in genetic medicine, this page offers a structured view of how the company reports its activities to regulators and the market, from clinical and regulatory milestones to manufacturing and partnership developments.
MeiraGTx Holdings plc Chief Medical Officer Robert K. Zeldin filed a Form 4 showing routine equity compensation activity. On January 7, 2026, 17,500 restricted share units granted on January 7, 2022 vested, with each unit converting into one ordinary share. To cover taxes on this vesting, 6,729 ordinary shares were withheld at a price of $7.73 per share rather than being sold in the open market.
After these transactions, Zeldin directly beneficially owned 147,291 ordinary shares of MeiraGTx. The filing reflects compensation-related vesting and associated tax withholding rather than discretionary market buying or selling.
MeiraGTx Holdings plc’s general counsel and secretary, Robert J. Wollin, reported routine equity award activity involving the company’s ordinary shares. On January 7, 2026, one quarter of his restricted share units granted on January 7, 2022 vested, converting 7,500 restricted share units into 7,500 ordinary shares at an exercise price of $0. In connection with this vesting, 4,364 ordinary shares were withheld at a price of $7.73 per share to cover tax obligations. After these transactions, he directly beneficially owned 29,282 ordinary shares of MeiraGTx.
MeiraGTx Holdings plc’s Chief Development Officer Stuart Naylor reported routine equity award activity involving restricted share units and ordinary shares. On January 7, 2026, 37,500 restricted share units vested and converted into the same number of ordinary shares, reflecting one-quarter of an award granted on January 7, 2022. Each restricted share unit converts into one ordinary share upon vesting. To cover tax withholding on this vesting, 17,625 ordinary shares were withheld at a price of $7.73 per share. After these transactions, Naylor directly held 643,166 ordinary shares of MeiraGTx Holdings plc.
MeiraGTx Holdings plc President & CEO and director Alexandria Forbes reported equity award activity in a Form 4. On January 7, 2026, one-quarter of a prior grant of restricted share units vested, converting 62,500 restricted share units granted on January 7, 2022 into the same number of ordinary shares on a one-for-one basis. To cover tax obligations on this vesting, 34,074 ordinary shares were withheld at a price of $7.73 per share. Following these transactions, Forbes directly beneficially owns 1,336,159 ordinary shares of MeiraGTx.
MeiraGTx Holdings plc (MGTX)
MeiraGTx Holdings (MGTX) reported a wider quarterly loss and tighter liquidity. For the three months ended September 30, 2025, total revenue was $410 thousand versus $10.9 million a year ago, driven by lower related-party service revenue. Operating expenses were $46.5 million, leading to a loss from operations of $46.1 million and a net loss of $50.5 million (basic and diluted loss per share $0.62).
Cash and cash equivalents fell to $14.8 million from $103.7 million at year-end, and shareholders’ equity moved to a $(40.6) million deficit as accumulated deficit reached $831.3 million. The company used $93.0 million in operating cash in the first nine months.
Management highlights pending strategic funding: an expected $200 million upfront from Hologen in Q4 2025 (with $28.0 million received during the period and an additional $22.0 million deposit in Q4 to date), up to $230 million of additional Hologen funding, and a $75.0 million upfront from Eli Lilly. Together with tax incentives and receivables, these are expected to fund operations for at least twelve months. Ordinary shares outstanding were 80,490,889 as of October 28, 2025.
MeiraGTx (MGTX) announced a strategic collaboration and license with Eli Lilly focused on ophthalmology genetic medicines. MeiraGTx will receive an upfront payment of $75 million and is eligible for up to over $400 million in total milestone payments, including up to $135 million tied to development and regulatory milestones. Lilly receives exclusive, worldwide rights to develop and commercialize the AAV-AIPL1 program for LCA4 and two additional preclinical retinal candidates.
Lilly also receives exclusive licenses to proprietary intravitreal capsids and pan‑retinal/rod‑specific promoters for up to five ophthalmology targets each, plus a right of first designation on certain target-specific transactions and a right of first negotiation for MeiraGTx’s riboswitch technology in ophthalmological gene editing. Lilly will fund research, development and commercialization, and MeiraGTx Ocular will receive tiered royalties. The agreement includes standard IP ownership provisions and is terminable for uncured material breach; Lilly may also terminate in whole, by product, or by country with notice.
MeiraGTx Holdings plc (MGTX) reported an insider transaction: CFO & COO Richard Giroux sold 24,000 ordinary shares on Oct 21, 2025 at a $8.87 weighted average pursuant to a Rule 10b5-1 trading plan adopted Aug 29, 2024.
Sale prices ranged from $8.65 to $9.06. After the transaction, he beneficially owns 829,494 shares directly, plus 5,152 indirectly via spouse and 85,000 indirectly via Aigle Healthcare Partners III LLC.
FAQ
What is the current stock price of Meiragtx Holdings Plc (MGTX)?
What is the market cap of Meiragtx Holdings Plc (MGTX)?
